Japanese electrical products manufacturer TWINBIRD Corporation (TOKYO:6897) on Tuesday announced the SC-UF25 Ultra-Low Temperature Portable Freezer, a compact 25-litre unit capable of reaching −86 degrees C, with commercial release scheduled for November 2026.
The product expands the company's portfolio of Free-Piston Stirling Cooler technology, using helium gas as a refrigerant to support ultra-low-temperature storage and transport of research samples.
Designed for laboratories and life-science organisations, the SC-UF25 offers temperature adjustment from −86C to −20C in 1-degree increments, low-vibration operation and compatibility with 100–240 V power supplies. The freezer aims to reduce reliance on dry ice, improving temperature stability and operational efficiency in cold-chain management for regenerative medicine, cell therapy and drug discovery research.
The product incorporates precision components manufactured in Japan's Tsubame-Sanjo region and is designed for use in laboratories with limited installation space.
TWINBIRD will showcase the SC-UF25 at MEDICA 2026 in Düsseldorf, Germany, from 16 to 19 November, highlighting its potential for research and laboratory cold-chain applications.
The company stated that the freezer is intended exclusively for research, laboratory and life-science cold-chain use and is not registered under the EU Medical Device Regulation or intended for clinical or patient-care applications.
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
FDA approves Vantis Vascular's 6F CrossFAST model
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Okami Medical receives FDA approval for expanded indication of LOBO Vascular Occluder
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Insmed's ARIKAYCE sNDA granted priority review by FDA
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
Aptar and Aceso Therapeutics partner to advance inhaled cystic fibrosis therapy